ROS1 and non-small cell lung carcinoma: Examples include Darzalex® (Daratumumab, OD indication: relapsed or refractory multiple myeloma, in 2017 → OD indication: multiple myeloma, in 2019, Janssen Pharmaceutical K.K.)and Xalkori® (Crizotinib, OD indication: ALK fusion gene-positive advanced non–small-cell lung cancer, in 2012 → OD indication: ROS1 fusion gene-positive unresectable advanced or recurrent non-small-cell lung cancer, in 2017, Pfizer Japan Inc.).